Akebia Ther (AKBA)vsUnited Therapeutics Corporation (UTHR)
AKBA
Akebia Ther
$0.50
-13.20%
HEALTHCARE · Cap: $195.78M
UTHR
United Therapeutics Corporation
$593.31
-0.39%
HEALTHCARE · Cap: $25.07B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 1355% more annual revenue ($3.19B vs $219.06M). UTHR leads profitability with a 38.6% profit margin vs -13.5%. UTHR earns a higher WallStSmart Score of 55/100 (C).
AKBA
Avoid24
out of 100
Grade: F
UTHR
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AKBA.
Margin of Safety
+2.4%
Fair Value
$487.71
Current Price
$593.31
$105.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 39 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.0%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -74.9% — below average capital efficiency
Expensive relative to growth rate
4.1% revenue growth
Earnings declined 20.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : AKBA
AKBA has a balanced fundamental profile.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Altman Z-Score, Operating Margin. Profitability is solid with margins at 38.6% and operating margin at 29.0%.
Bear Case : AKBA
The primary concerns for AKBA are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.16 is elevated, increasing financial risk.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
AKBA profiles as a turnaround stock while UTHR is a value play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.48 — expect wider price swings.
UTHR is growing revenue faster at 4.1% — sustainability is the question.
UTHR generates stronger free cash flow (126M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (55/100 vs 24/100), backed by strong 38.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akebia Ther
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?